Fifteen years ago, following the increased circulation of avian influenza in the early 2000s, and in recognition of the ever-present threat of pandemic influenza, WHO Member States developed and adopted the PIP Framework, a cornerstone of global pandemic preparedness. The PIP Framework aims to improve pandemic influenza preparedness and response through promoting the sharing of influenza viruses with human pandemic potential (IVPP), investing in countries to strengthen pandemic influenza detection and response capacities, and working with industry to ensure real-time access to pandemic influenza response products.
Its achievements are the result of a truly global effort: implemented across WHO Headquarters, Regional Offices and Country Offices, and supported by Member States, GISRS, Industry & Associations, Civil Society Organizations and other partners, all of whom have helped turn the Framework into real-world impact.
"The uniqueness of that model is that it doesn't wait for the pandemic to unlock its resources... it builds systems that make pandemics - less catastrophic and it does that quietly, persistently, and equitably even when the world is not watching."
– Dr Farida Al Hosani, CEO, Global Institute for Disease Elimination (GLIDE)
“The PIP Framework is one pristine example of how to put on an equal footing access and benefit sharing.”
– Dr Hugo López-Gatell, Minister and Head of Health Affairs, Permanent Mission of Mexico to the UN office in Geneva
“We sincerely appreciate the support provided through the PIP PC fund, which has significantly contributed to strengthening Armenia’s national capacity for influenza surveillance and pandemic preparedness. This partnership continues to play a vital role in protecting public health.”
– Dr Stepan Atoyan, Director General, National Center for Disease Control and Prevention, Armenia
“WHO’s support through the PIP Framework has been a game changer in advancing EDA regulatory capabilities. This strategic collaboration was key to achieving WHO GBT Maturity Level 3—making Egypt the first country in Africa to reach this milestone for both vaccine and medicine regulation. We proudly see this achievement as a commitment to our region and the world, as it has equipped EDA with a more resilient regulatory system— ensuring timely response during pandemics and beyond, greater access to quality-assured products, and ultimately, saving lives."
– Dr Ali Elghamrawy, Chairman of the Egyptian Drug Authority, Egypt
The PIP framework has been a fundamental pillar in strengthening our capacities, especially in the laboratory area, enhancing diagnostic response, surveillance, and technical staff training across Bolivia’s national network.”
– Dr Nelly Mendoza Loayza, Chief of the Laboratory Services Unit, National Center for Tropical Diseases, Bolivia